Pacific Biosciences Of California (PACB) Amortization of Deferred Charges (2013 - 2026)

Pacific Biosciences Of California's Amortization of Deferred Charges history runs 14 years deep, the most recent figure standing at $849000.0 for Q1 2026.

• On a quarterly basis, Amortization of Deferred Charges fell 32.51% year-over-year to $849000.0 in Q1 2026; TTM through Mar 2026 was $3.6 million, a 68.98% decrease from a year earlier, with the FY2025 full-year figure at $4.0 million, down 67.31% from the prior year.
• Amortization of Deferred Charges eased to $849000.0 in Q1 2026 per PACB's latest filing, from $894000.0 in the prior quarter.
• Across five years, Amortization of Deferred Charges topped out at $5.1 million in Q3 2024 and bottomed at $154000.0 in Q2 2022.
• The 5-year median for Amortization of Deferred Charges is $1.3 million (2025), against an average of $1.5 million.
• Across the five-year window, Amortization of Deferred Charges surged 2440.0% in 2024 and slumped 81.78% in 2025, its largest moves.
• Year by year, Amortization of Deferred Charges stood at $1.8 million in 2022, then climbed by 5.47% to $1.9 million in 2023, then slumped by 32.99% to $1.3 million in 2024, then slipped by 28.65% to $894000.0 in 2025, then retreated by 5.03% to $849000.0 in 2026.
• Per Business Quant, the three latest PACB Amortization of Deferred Charges figures stand at $849000.0 (Q1 2026), $894000.0 (Q4 2025), and $921000.0 (Q3 2025).